By Julie Steenhuysen CHICAGO (Reuters) -Thousands of Americans campaigning for the Novavax COVID-19 booster got some good ...

Under emergency use, vaccines can be removed even after a health emergency is considered to be over. Full approval from the ...

Novavax says its closely watched COVID-19 vaccine is on track for full U.S. approval after additional discussions with the ...

Novavax said on Wednesday U.S. regulators asked the company to produce more data on its COVID-19 vaccine if it gets full ...

Novavax on Wednesday said the U.S. Food and Drug Administration has asked the company to commit to produce more data on its ...

The FDA is asking Novavax for a non-mandatory postmarketing commitment to produce additional clinical data for its ...

Novavax's COVID-19 vaccine showed fewer side effects than Pfizer's in a Utah study as FDA seeks more data before full ...

The FDA is considering the approval of the Novavax COVID-19 booster after delays amid controversy over its non-mRNA design.

Novavax, the little-known Maryland company that received a $1.6 billion deal from the federal government for its experimental coronavirus vaccine, announced encouraging results in two preliminary ...

On a recent call with analysts at BMO Capital Markets, a “former director” at the FDA’s Center for Biologics Evaluation and ...

Novavax Inc. shares rose after US regulators asked for more data on its Covid vaccine, signaling the shot may be on a path to ...

The company said the FDA issued a formal information request tied to its Biologics License Application (BLA) and asked for a ...